

**Alaska Medicaid Pharmacy and Therapeutics Committee**

| <b>FY 2017 P&amp;T Proposed Drug Class Review Schedule</b> |  |  |
|--|--|--|
| <b>November 18, 2016</b>                                   | <b>January 20, 2017</b>                      | <b>April 21, 2017</b>                      |
| <b>CENTRAL NERVOUS SYSTEM</b>                              | <b>CARDIOVASCULAR</b>                        | <b>RESPIRATORY / ALLERGY</b>               |
| Alzheimers Agents  | ACE-Inhibitors & Renin Inhibitors            | Antihistamines, Minimally Sedating         |
| Anticonvulsants  | Angiotensin Receptor Blockers                | Beta Agonist Bronchodilators, Long-Acting  |
| Antidepressants, Other                                     | Angiotensin Modulator / CCB Combinations     | Beta Agonist Bronchodilators, Short-Acting |
| Antidepressants, SNRI                                      | Antianginal and Anti-Ischemic                | COPD Agents                                |
| Antidepressants, SSRI                                      | Anticoagulants                               | Epinephrine, Self-Injected                 |
| Antipsychotics – Atypical                                  | Beta- Blockers                               | Glucocorticoids, Inhaled, Single Agent     |
| Multiple Sclerosis Agents                                  | Calcium Channel Blockers                     | Glucocorticoids, Inhaled, Combination      |
| Sedative Hypnotics   | Erythropoiesis Stimulators                   | Immunomodulators, Asthma                   |
| Stimulants & Related Agents                                | **Iron Chelators                             | Intranasal Rhinitis Agents                 |
|  | Lipotropics, Other                           | Leukotriene Modifiers                      |
| <b>SUBSTANCE DEPENDENCE</b>                                | **Lipotropics, PCSK-9 Inhibitors             | **Mucolytics                               |
| Opioid Dependence  | Platelet Aggregation Inhibitors              |  |
| Smoking Cessation Products                                 | Pulmonary Arterial Hypertension (PAH) Agents | <b>IMMUNOLOGICAL</b>                       |
|  |  | **Colony-Stimulating Factor (CSF) Agents   |
| <b>ANALGESICS</b>  | <b>GENITOURINARY</b>                         | Immunosuppressives, Oral                   |
| Antimigraine Agents  | BPH Agents                                   | **IVIg (Immune Globulin)                   |
| Long-Acting Opioid Analgesics                              | Bladder Relaxant Preparations                |  |
| **Short-Acting Narcotic Analgesics                         | Vaginal Antibiotics                          | <b>ANTI-INFECTIVE</b>                      |
| Neuropathic Pain   |  | Antifungals, Oral                          |
| NSAIDs   | <b>GASTROINTESTINAL</b>                      | Antifungals, Topical                       |
| Restless Leg Syndrome (RLS)                                | Antiemetic-Antivertigo Agents                | Antivirals, Influenza                      |
| Skeletal Muscle Relaxants                                  | **Bowel Preps – Laxatives & Cathartics       | Antivirals, Topical                        |
|  | Cytokine & CAM Antagonist - GI Indications   | Fluoroquinolones, Oral                     |
| <b>CYSTIC FIBROSIS</b>                                     | **Helicobacter Pylori Treatment              | Hepatitis B Agents                         |
| Inhaled Antibiotics  | IBS & GI Motility, Chronic                   | **HIV Treatments                           |
| **Oral CF Agents, CFTR Potentiators                        | Ulcerative Colitis                           |  |
| Pancreatic Enzymes   |  | <b>DERMATOLOGIC</b>                        |
|  | <b>ENDOCRINE/ METABOLIC</b>                  | Acne, Topical                              |
| <b>OPHTHALMIC</b>  | Alpha-Glucosidase Hypoglycemic               | **Antiparasitics, Topical                  |
| Allergic Conjunctivitis                                    | Incretin Mimetic/ Enhancer Hypoglycemics     | Antipsoriasis                              |
| Antibiotic   | Insulins                                     | Immunomodulators, Atopic Dermatitis        |
| Antibiotic-Steroid Combination                             | Meglitinide Hypoglycemics                    | Steroids, Topical Low Potency              |
| Anti-Inflammatory  | Metformin Hypoglycemics                      | Steroids, Topical Med. Potency             |
| Glaucoma Ophthalmics                                       | SGLT2 Hypoglycemics                          | Steroids, Topical High Potency             |
| Immunomodulator  | Thiazolidinedione (TZD)                      | Steroids, Topical Very High Potency        |
|  | Androgenic Agents, Topical                   |  |
| <b>SPECIALTY / ANTI-INFECTIVE</b>                          | Antihyperuricemics                           | <b>SPECIALTY DRUG CLASSES</b>              |
| Hepatitis C Agents, DAA                                    | Bone Resorption Inhibitors                   | **Hereditary Angioedema Agents             |
| Hepatitis C Agents, Other                                  | Cytokine & CAM Antagonist- No GI Indication  | **Oncology Agents, oral                    |
|  | Growth Hormone                               | **Hemophilia Prophylaxis Treatments        |
|  | Phosphate Binders                            |  |
|  | **Pituitary Suppressive Agents (LHRH)        |  |
|  | Progestins for Cachexia                      |  |
|  |  |  |
|  |  | **New classes to PDL                       |

Drug class listings are based on the anticipated review schedule for the identified dates but are subject to change. Please refer to the official meeting agenda publically noticed 30 days in advance of the meeting for the final agenda. <https://aws.state.ak.us/OnlinePublicNotices/default.aspx>